Vertex scores world-first approval

Vertex has won the first-ever regulatory approval of a therapy based on the CRISPR gene-editing technology, with the UK's MHRA giving it the tick for two indications, sickle cell disease and transfusion-dependent beta-thalassaemia.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here